Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma

Table 1 Baseline characteristics of the patients

Characteristic	D-TACE-P-L group (n = 50)	C-TACE-P-L group (n = 54)	P value
Sex, n (%)			0.564
Male	42 (84.0)	43 (79.6)
Female	8 (16.0)	11 (20.4)
Age (years), mean ± SD	60.8 ± 9.2	62.2 ± 9.4	0.443
ECOG PS, n (%)			0.252
0	14 (28.0)	10 (18.5)
1	36 (72.0)	44 (81.5)
Child-Pugh class, n (%)			0.561
A	26 (52.0)	25 (46.3)
B	24 (48.0)	29 (53.7)
BCLC, n (%)			0.556
B	14 (28.0)	18 (33.3)
C	36 (72.0)	36 (66.7)
AFP, n (%)			0.727
≤ 400 ng/mL	23 (46.0)	23 (42.6)
> 400 ng/mL	27 (54.0)	31 (57.4)
Number of tumors, n (%)			0.392
≤ 3	31 (62)	29 (53.7)
> 3	19 (38)	25 (46.3)
Largest tumor size (mm), mean ± SD	96.3 ± 27.7	91.0 ± 36.7	0.324
PVTT, n (%)			0.873
No	23 (46.0)	24 (44.4)
Yes	27 (54.0)	30 (55.6)
Hepatic vein invasion, n (%)			0.656
No	38 (76.0)	43 (20.4)
Yes	12 (24.0)	11 (79.6)
Extrahepatic metastasis, n (%)			0.661
No	41 (82.0)	46 (85.2)
Yes	9 (18.0)	8 (14.8)
Number of TACE, mean ± SD	2.46 ± 1.0	2.56 ± 1.1	0.640

C-TACE-P-L: Conventional transarterial chemoembolization combined with lenvatinib plus programmed cell death 1 inhibitor; D-TACE-P-L: Drug-eluting beads transarterial chemoembolization combined with lenvatinib plus programmed cell death 1 inhibitor; ECOG PS: Eastern Cooperative Oncology Group Performance Status; BCLC: Barcelona Clinic Liver Cancer; AFP: Alpha-fetoprotein; PVTT: Portal vein tumor thrombus; TACE: Transarterial chemoembolization.